Limitations and lessons in the use of X-ray structural information in drug design.
Davis
Andrew M
AM
Department of Medicinal Chemistry, AstraZeneca R&D Charnwood, Bakewell Road, Loughborough, Leicestershire LE11 5RH, United Kingdom. andy.davis@astrazeneca.com
St-Gallay
Stephen A
SA
Kleywegt
Gerard J
GJ
D000818:Animals; D018360:Crystallography, X-Ray; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000138:chemical synthesis / Q000494:pharmacology; D006801:Humans; D008024:Ligands; D009682:Magnetic Resonance Spectroscopy; D008958:Models, Molecular; D052247:Nitric Oxide Synthase Type II / Q000037:antagonists & inhibitors; D011506:Proteins / Q000737:chemistry
D004791:Enzyme Inhibitors; D008024:Ligands; D011506:Proteins; D052247:Nitric Oxide Synthase Type II